Merck & Co. Investing Cash Flow increased by 8.8% to -$10.21B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 586.6%, from -$1.49B to -$10.21B. Over 4 years (FY 2021 to FY 2025), Investing Cash Flow shows an upward trend with a -4.4% CAGR.
A negative value typically signals investment in future growth, while a positive value may indicate divestment or the maturity of a large investment portfolio.
This metric is the net total of all cash inflows and outflows related to investing activities, including capital expendi...
Most mature healthcare companies maintain a negative net investing cash flow due to ongoing R&D and infrastructure investment.
net_cash_from_investing| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$2.57B | -$1.06B | -$12.05B | -$1.17B | -$1.08B | -$962.00M | -$1.75B | -$2.36B | -$11.44B | -$334.00M | $0.00 | -$1.38B | -$1.07B | -$3.85B | -$1.44B | -$1.49B | -$770.00M | -$283.00M | -$11.20B | -$10.21B |
| QoQ Change | — | +58.8% | <-999% | +90.3% | +8.2% | +10.7% | -81.7% | -35.0% | -385.1% | +97.1% | +100.0% | — | +22.3% | -259.7% | +62.4% | -3.0% | +48.2% | +63.2% | <-999% | +8.8% |
| YoY Change | — | — | — | — | +58.1% | +9.3% | +85.5% | -101.1% | -962.5% | +65.3% | +100.0% | +41.7% | +90.7% | <-999% | — | -8.1% | +28.0% | +92.6% | -675.7% | -586.6% |